Critical Reviews in Oncology/Hematology
Издатель: Elsevier · ISSN 1040-8428 · 70 статей
- Antibody–Drug Conjugates in Oncology: Clinical Implementation, Toxicity Management, and Evolving Treatment Strategies
- How Cancer-Associated Fibroblasts Regulate NK Cell Receptors, Ligands, and Function in the Tumor Microenvironment
- Cyclin-Dependent Kinase 4/6 Inhibitors in Non-Breast Malignancies
- T-cell engagers in small-cell lung cancer: from development to safety management of a breakthrough immunotherapy strategy for solid tumors
- MicroRNAs and Long Non-coding RNAs in Gastric Cancer: Epigenetic Regulation, Disease Progression, and Clinical Translation
- Biosimilars in oncology: A decade of experience with granulocyte colony-stimulating factor and its implications for monoclonal antibodies
- Advances in Next-Generation Sequencing and Single-Cell Transcriptomics for Profiling NK Cell Heterogeneity and Functional Diversity in Cancer
- Improving the Quality of Care in Advanced Prostate Cancer Through Personalised Diagnostic Testing. Outcomes of a Sharing Progress in Cancer Care taskforce conducted under the auspices of the European Association of Urology
- B3GNT3 in cancer: Catalysis-dependent and catalysis-independent mechanisms, biomarker readiness and therapeutic targeting
- Beyond the generic tumor: Engineering patient-specific immune ecosystems for cancer
- Spatial Niches Shape Function in the Intratumoral Microbiome: From Multiscale Mapping to Niche-Informed Therapy
- Engineering Immune Effector Cells from iPSCs: From Reprogramming Biology to Next-Generation CAR Therapies
- MAIT cells in tumor contexts: Functional diversity and regulatory hierarchies
- Targeting Protein Tyrosine Phosphatases in Cancer: Dual Roles and Therapeutic Implications
- Adding Immune Checkpoint Inhibitors to Bladder-Preservation Therapy in Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis
- ERα-Targeting PROTACs in Breast Cancer: Structural Design, Biological Mechanisms, Clinical Translation, and Implications for Multimodal Management
- Guilty by marker? Reassessing the pro-tumor reputation of antigen-presenting M2-like macrophages
- Long Non-Coding RNAs in Cancer Epigenetic and Epitranscriptomic Modulation: Mechanisms and Clinical Applications as Potential Biomarkers
- Spatial organization of tumor-associated macrophage states: Niche-dependent immune bottlenecks and therapy-driven adaptation
- Targeting adipose tissue-vascular crosstalk in tumor angiogenesis
- Post-transcriptional regulation in cancer dormancy: An underappreciated regulatory layer
- Integrating physical exercise into breast cancer care: Implications for tumor development
- Methodological heterogeneity in the assessment of X chromosome inactivation in cancer: A systematic review
- Survival by design: Cell fate dynamics in classical Hodgkin lymphoma
- Blood-based mass spectrometry in plasma cell disorders: From residual secretory activity to multimodal residual disease assessment
- The efficacy of immune-checkpoint inhibitors in combination with definitive chemoradiotherapy in non-metastatic esophageal SCC: A systematic review and meta-analysis
- Immunosenescence in tumor progression: From synergistic mechanisms to therapeutic strategies
- The impact of the tumor microenvironment on immune checkpoint inhibitor resistance in prostate cancer: Mechanistic insights and therapeutic strategies
- Reprogramming the myeloid–T cell ecosystem through engineered oncolytic viruses for durable antitumor immunity
- Tumor-associated immunosenescence: Mechanisms, biomarkers and age-adaptive immunotherapy